Raymond James Cuts Alnylam Price Target to $315, Downgrades Rating
Raymond James lowered its Alnylam Pharmaceuticals price target to $315 from $420 and cut its rating to Outperform from Strong Buy.
Raymond James lowered its Alnylam Pharmaceuticals price target to $315 from $420 and cut its rating to Outperform from Strong Buy.